Interferons, effective molecules against coronavirus? According to a study carried out in China on interferon alpha-2b that showed some effectiveness in the reduction of the inflammation (the famous cytokine storms) in case of respiratory distress, it is now pharmaceutical company Synairgen to show results of its clinical trials on interferon beta, this time, a molecule naturally produced by the human body, and that could – according to the study – lower the risks of developing severe coronavirus.
“a major breakthrough in the treatment of hospitalized COVID-19 patients” the British biotechnology company commented as they release the results of their clinical trial themselves. According to the double-blinded study carried out on 1010 patients in nine hospitals across the country, interferon beta – usually given as a treatment against sclerosis – enabled to “very significatively” lower short of breath in patients hospitalized. According to Ouest France, “the treatment reduces by 79% the risks of developing a serious disease in people hospitalized requiring ventilation”. Note that it could also reduce hospitalization time from 9 to 6 days.
How does this treatment work? In consists in inhaling the protein though a nebulizer, it directly ends up in the lungs a trigger “a stronger anti-viral response, even in patients whose immune systems are already weak.” A promising treatment that has yet to be studied in other trials to confirm is effectiveness. Unless it is directly put on circulation after being urgently approved as for remdesivir, the first treatment allowed by prescription by the European Union to fight against coronavirus.